Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

Jing Zou(The University of Texas Medical Branch at Galveston), Chaitanya Kurhade(The University of Texas Medical Branch at Galveston), Sohil Patel(Pfizer (United Kingdom)), Nicholas Kitchin(Pfizer (United Kingdom)), Kristin Tompkins(Pfizer (United States)), Mark Cutler(Pfizer (United States)), David Cooper(Pfizer (United States)), Qi Yang(Pfizer (United States)), Hui Cai(Pfizer (United States)), Alexander Muik(BioNTech (Germany)), Ying Zhang(Pfizer (United States)), Dung-Yang Lee(Pfizer (United States)), Uğur Şahin(BioNTech (Germany)), Annaliesa S. Anderson(Pfizer (United States)), William C. Gruber(Pfizer (United States)), Xuping Xie(The University of Texas Medical Branch at Galveston), Kena A. Swanson(Pfizer (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston)
New England Journal of Medicine
January 25, 2023
10.1056/nejmc2214916
Cited by 176Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis